Clinical trial
A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder
NCT07931703 is registered in ClinicalTrials.gov with Gedeon Richter Plc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder
- Lead sponsor
- Gedeon Richter Plc.
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 12, 2026
- Completion date
- February 13, 2028
- Enrollment
- 156 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
social anxiety disorder
Arms
As registered; 2 arms.
-
Group receiving RGH-202
Oral capsule dosage form applied once daily for 42 days
-
Group receiving Placebo
Oral capsule dosage form applied once daily for 42 days
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Incidence and severity of adverse events
Lead sponsor's other trials
Gedeon Richter Plc., most recent start first.
+7 more trials
Similar trials
Same condition (Phobia, Social) and phase, most recent start first.
+30 more trials See the condition page